nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—Application site pain—Fluorouracil—colon cancer	0.0258	0.0258	CcSEcCtD
Ceftazidime—Local reaction—Fluorouracil—colon cancer	0.0205	0.0205	CcSEcCtD
Ceftazidime—Myoclonus—Vincristine—colon cancer	0.0202	0.0202	CcSEcCtD
Ceftazidime—Prothrombin level increased—Capecitabine—colon cancer	0.0193	0.0193	CcSEcCtD
Ceftazidime—Gastrointestinal symptom NOS—Fluorouracil—colon cancer	0.0193	0.0193	CcSEcCtD
Ceftazidime—Reaction gastrointestinal—Methotrexate—colon cancer	0.0177	0.0177	CcSEcCtD
Ceftazidime—Encephalopathy—Fluorouracil—colon cancer	0.0177	0.0177	CcSEcCtD
Ceftazidime—Myoclonus—Capecitabine—colon cancer	0.0132	0.0132	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Irinotecan—colon cancer	0.013	0.013	CcSEcCtD
Ceftazidime—Oral candidiasis—Capecitabine—colon cancer	0.0125	0.0125	CcSEcCtD
Ceftazidime—Nephropathy—Methotrexate—colon cancer	0.0124	0.0124	CcSEcCtD
Ceftazidime—Encephalopathy—Capecitabine—colon cancer	0.0124	0.0124	CcSEcCtD
Ceftazidime—Inflammation—Fluorouracil—colon cancer	0.0117	0.0117	CcSEcCtD
Ceftazidime—Colitis—Irinotecan—colon cancer	0.0114	0.0114	CcSEcCtD
Ceftazidime—Coma—Vincristine—colon cancer	0.0111	0.0111	CcSEcCtD
Ceftazidime—Coma—Fluorouracil—colon cancer	0.0104	0.0104	CcSEcCtD
Ceftazidime—Thrombophlebitis—Irinotecan—colon cancer	0.00994	0.00994	CcSEcCtD
Ceftazidime—Injection site pain—Capecitabine—colon cancer	0.00972	0.00972	CcSEcCtD
Ceftazidime—Thrombophlebitis—Fluorouracil—colon cancer	0.00952	0.00952	CcSEcCtD
Ceftazidime—Encephalopathy—Methotrexate—colon cancer	0.0092	0.0092	CcSEcCtD
Ceftazidime—Renal impairment—Irinotecan—colon cancer	0.00904	0.00904	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Capecitabine—colon cancer	0.00873	0.00873	CcSEcCtD
Ceftazidime—Lethargy—Fluorouracil—colon cancer	0.00841	0.00841	CcSEcCtD
Ceftazidime—Inflammation—Capecitabine—colon cancer	0.00818	0.00818	CcSEcCtD
Ceftazidime—Colitis—Capecitabine—colon cancer	0.00762	0.00762	CcSEcCtD
Ceftazidime—Candida infection—Capecitabine—colon cancer	0.00758	0.00758	CcSEcCtD
Ceftazidime—Skin exfoliation—Capecitabine—colon cancer	0.00758	0.00758	CcSEcCtD
Ceftazidime—Pancytopenia—Vincristine—colon cancer	0.00725	0.00725	CcSEcCtD
Ceftazidime—Neutropenia—Vincristine—colon cancer	0.00714	0.00714	CcSEcCtD
Ceftazidime—Eosinophilia—Fluorouracil—colon cancer	0.00705	0.00705	CcSEcCtD
Ceftazidime—Neutropenia—Irinotecan—colon cancer	0.00696	0.00696	CcSEcCtD
Ceftazidime—Pancytopenia—Fluorouracil—colon cancer	0.00677	0.00677	CcSEcCtD
Ceftazidime—Phlebitis—Capecitabine—colon cancer	0.00669	0.00669	CcSEcCtD
Ceftazidime—Thrombophlebitis—Capecitabine—colon cancer	0.00665	0.00665	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Capecitabine—colon cancer	0.00659	0.00659	CcSEcCtD
Ceftazidime—Renal failure—Irinotecan—colon cancer	0.00652	0.00652	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Methotrexate—colon cancer	0.0065	0.0065	CcSEcCtD
Ceftazidime—Jaundice—Irinotecan—colon cancer	0.00647	0.00647	CcSEcCtD
Ceftazidime—Haemolytic anaemia—Capecitabine—colon cancer	0.00638	0.00638	CcSEcCtD
Ceftazidime—Infestation NOS—Fluorouracil—colon cancer	0.00635	0.00635	CcSEcCtD
Ceftazidime—Infestation—Fluorouracil—colon cancer	0.00635	0.00635	CcSEcCtD
Ceftazidime—Hot flush—Capecitabine—colon cancer	0.00616	0.00616	CcSEcCtD
Ceftazidime—Menopausal symptoms—Capecitabine—colon cancer	0.00611	0.00611	CcSEcCtD
Ceftazidime—Inflammation—Methotrexate—colon cancer	0.00609	0.00609	CcSEcCtD
Ceftazidime—Hallucination—Vincristine—colon cancer	0.00608	0.00608	CcSEcCtD
Ceftazidime—Renal impairment—Capecitabine—colon cancer	0.00605	0.00605	CcSEcCtD
Ceftazidime—Haemoglobin—Irinotecan—colon cancer	0.00598	0.00598	CcSEcCtD
Ceftazidime—Haemorrhage—Irinotecan—colon cancer	0.00595	0.00595	CcSEcCtD
Ceftazidime—Agranulocytosis—Fluorouracil—colon cancer	0.00593	0.00593	CcSEcCtD
Ceftazidime—Vaginal inflammation—Methotrexate—colon cancer	0.00591	0.00591	CcSEcCtD
Ceftazidime—Lethargy—Capecitabine—colon cancer	0.00588	0.00588	CcSEcCtD
Ceftazidime—Haemoglobin—Fluorouracil—colon cancer	0.00573	0.00573	CcSEcCtD
Ceftazidime—Haemorrhage—Fluorouracil—colon cancer	0.0057	0.0057	CcSEcCtD
Ceftazidime—Skin exfoliation—Methotrexate—colon cancer	0.00564	0.00564	CcSEcCtD
Ceftazidime—Vaginal infection—Methotrexate—colon cancer	0.00558	0.00558	CcSEcCtD
Ceftazidime—Angiopathy—Vincristine—colon cancer	0.00555	0.00555	CcSEcCtD
Ceftazidime—Aplastic anaemia—Methotrexate—colon cancer	0.00555	0.00555	CcSEcCtD
Ceftazidime—Flushing—Irinotecan—colon cancer	0.00553	0.00553	CcSEcCtD
Ceftazidime—Angiopathy—Irinotecan—colon cancer	0.0054	0.0054	CcSEcCtD
Ceftazidime—Coma—Methotrexate—colon cancer	0.0054	0.0054	CcSEcCtD
Ceftazidime—Immune system disorder—Irinotecan—colon cancer	0.00538	0.00538	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.00519	0.00519	CcSEcCtD
Ceftazidime—Thrombophlebitis—Methotrexate—colon cancer	0.00495	0.00495	CcSEcCtD
Ceftazidime—Bronchospasm—Capecitabine—colon cancer	0.0049	0.0049	CcSEcCtD
Ceftazidime—Agitation—Vincristine—colon cancer	0.00489	0.00489	CcSEcCtD
Ceftazidime—Leukopenia—Vincristine—colon cancer	0.00476	0.00476	CcSEcCtD
Ceftazidime—Pancytopenia—Capecitabine—colon cancer	0.00473	0.00473	CcSEcCtD
Ceftazidime—Vision blurred—Fluorouracil—colon cancer	0.00468	0.00468	CcSEcCtD
Ceftazidime—Neutropenia—Capecitabine—colon cancer	0.00466	0.00466	CcSEcCtD
Ceftazidime—Leukopenia—Irinotecan—colon cancer	0.00464	0.00464	CcSEcCtD
Ceftazidime—Convulsion—Vincristine—colon cancer	0.00461	0.00461	CcSEcCtD
Ceftazidime—Leukopenia—Fluorouracil—colon cancer	0.00444	0.00444	CcSEcCtD
Ceftazidime—Infestation—Capecitabine—colon cancer	0.00444	0.00444	CcSEcCtD
Ceftazidime—Infestation NOS—Capecitabine—colon cancer	0.00444	0.00444	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.0044	0.0044	CcSEcCtD
Ceftazidime—Lethargy—Methotrexate—colon cancer	0.00438	0.00438	CcSEcCtD
Ceftazidime—Renal failure—Capecitabine—colon cancer	0.00436	0.00436	CcSEcCtD
Ceftazidime—Anaphylactic shock—Vincristine—colon cancer	0.00434	0.00434	CcSEcCtD
Ceftazidime—Jaundice—Capecitabine—colon cancer	0.00433	0.00433	CcSEcCtD
Ceftazidime—Convulsion—Fluorouracil—colon cancer	0.0043	0.0043	CcSEcCtD
Ceftazidime—Nervous system disorder—Vincristine—colon cancer	0.00426	0.00426	CcSEcCtD
Ceftazidime—Thrombocytopenia—Vincristine—colon cancer	0.00425	0.00425	CcSEcCtD
Ceftazidime—Anaphylactic shock—Irinotecan—colon cancer	0.00423	0.00423	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Capecitabine—colon cancer	0.0042	0.0042	CcSEcCtD
Ceftazidime—Nervous system disorder—Irinotecan—colon cancer	0.00415	0.00415	CcSEcCtD
Ceftazidime—Agranulocytosis—Capecitabine—colon cancer	0.00414	0.00414	CcSEcCtD
Ceftazidime—Thrombocytopenia—Irinotecan—colon cancer	0.00414	0.00414	CcSEcCtD
Ceftazidime—Hypotension—Vincristine—colon cancer	0.00406	0.00406	CcSEcCtD
Ceftazidime—Anaphylactic shock—Fluorouracil—colon cancer	0.00405	0.00405	CcSEcCtD
Ceftazidime—Haemoglobin—Capecitabine—colon cancer	0.00401	0.00401	CcSEcCtD
Ceftazidime—Haemorrhage—Capecitabine—colon cancer	0.00399	0.00399	CcSEcCtD
Ceftazidime—Nervous system disorder—Fluorouracil—colon cancer	0.00397	0.00397	CcSEcCtD
Ceftazidime—Thrombocytopenia—Fluorouracil—colon cancer	0.00397	0.00397	CcSEcCtD
Ceftazidime—Hypotension—Irinotecan—colon cancer	0.00395	0.00395	CcSEcCtD
Ceftazidime—Paraesthesia—Vincristine—colon cancer	0.0039	0.0039	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.00386	0.00386	CcSEcCtD
Ceftazidime—Paraesthesia—Irinotecan—colon cancer	0.0038	0.0038	CcSEcCtD
Ceftazidime—Hypotension—Fluorouracil—colon cancer	0.00379	0.00379	CcSEcCtD
Ceftazidime—Erythema multiforme—Capecitabine—colon cancer	0.00377	0.00377	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Vincristine—colon cancer	0.00375	0.00375	CcSEcCtD
Ceftazidime—Pain—Vincristine—colon cancer	0.00371	0.00371	CcSEcCtD
Ceftazidime—Flushing—Capecitabine—colon cancer	0.0037	0.0037	CcSEcCtD
Ceftazidime—Eosinophilia—Methotrexate—colon cancer	0.00367	0.00367	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Irinotecan—colon cancer	0.00365	0.00365	CcSEcCtD
Ceftazidime—Paraesthesia—Fluorouracil—colon cancer	0.00364	0.00364	CcSEcCtD
Ceftazidime—Pain—Irinotecan—colon cancer	0.00362	0.00362	CcSEcCtD
Ceftazidime—Angiopathy—Capecitabine—colon cancer	0.00362	0.00362	CcSEcCtD
Ceftazidime—Immune system disorder—Capecitabine—colon cancer	0.0036	0.0036	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Vincristine—colon cancer	0.00355	0.00355	CcSEcCtD
Ceftazidime—Pancytopenia—Methotrexate—colon cancer	0.00352	0.00352	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Fluorouracil—colon cancer	0.0035	0.0035	CcSEcCtD
Ceftazidime—Neutropenia—Methotrexate—colon cancer	0.00347	0.00347	CcSEcCtD
Ceftazidime—Pain—Fluorouracil—colon cancer	0.00346	0.00346	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Irinotecan—colon cancer	0.00346	0.00346	CcSEcCtD
Ceftazidime—Body temperature increased—Vincristine—colon cancer	0.00343	0.00343	CcSEcCtD
Ceftazidime—Abdominal pain—Vincristine—colon cancer	0.00343	0.00343	CcSEcCtD
Ceftazidime—Dysgeusia—Capecitabine—colon cancer	0.0034	0.0034	CcSEcCtD
Ceftazidime—Abdominal pain—Irinotecan—colon cancer	0.00334	0.00334	CcSEcCtD
Ceftazidime—Body temperature increased—Irinotecan—colon cancer	0.00334	0.00334	CcSEcCtD
Ceftazidime—Infestation NOS—Methotrexate—colon cancer	0.0033	0.0033	CcSEcCtD
Ceftazidime—Infestation—Methotrexate—colon cancer	0.0033	0.0033	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.00328	0.00328	CcSEcCtD
Ceftazidime—Vision blurred—Capecitabine—colon cancer	0.00327	0.00327	CcSEcCtD
Ceftazidime—Tremor—Capecitabine—colon cancer	0.00325	0.00325	CcSEcCtD
Ceftazidime—Renal failure—Methotrexate—colon cancer	0.00325	0.00325	CcSEcCtD
Ceftazidime—Urticaria—Fluorouracil—colon cancer	0.00322	0.00322	CcSEcCtD
Ceftazidime—Body temperature increased—Fluorouracil—colon cancer	0.0032	0.0032	CcSEcCtD
Ceftazidime—Hypersensitivity—Vincristine—colon cancer	0.0032	0.0032	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Methotrexate—colon cancer	0.00313	0.00313	CcSEcCtD
Ceftazidime—Hypersensitivity—Irinotecan—colon cancer	0.00312	0.00312	CcSEcCtD
Ceftazidime—Leukopenia—Capecitabine—colon cancer	0.00311	0.00311	CcSEcCtD
Ceftazidime—Agranulocytosis—Methotrexate—colon cancer	0.00308	0.00308	CcSEcCtD
Ceftazidime—Hypersensitivity—Fluorouracil—colon cancer	0.00299	0.00299	CcSEcCtD
Ceftazidime—Haemoglobin—Methotrexate—colon cancer	0.00298	0.00298	CcSEcCtD
Ceftazidime—Diarrhoea—Vincristine—colon cancer	0.00297	0.00297	CcSEcCtD
Ceftazidime—Haemorrhage—Methotrexate—colon cancer	0.00297	0.00297	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00293	0.00293	CcSEcCtD
Ceftazidime—Diarrhoea—Irinotecan—colon cancer	0.00289	0.00289	CcSEcCtD
Ceftazidime—Dizziness—Vincristine—colon cancer	0.00287	0.00287	CcSEcCtD
Ceftazidime—Pruritus—Fluorouracil—colon cancer	0.00287	0.00287	CcSEcCtD
Ceftazidime—Erythema multiforme—Methotrexate—colon cancer	0.00281	0.00281	CcSEcCtD
Ceftazidime—Dizziness—Irinotecan—colon cancer	0.0028	0.0028	CcSEcCtD
Ceftazidime—Nervous system disorder—Capecitabine—colon cancer	0.00278	0.00278	CcSEcCtD
Ceftazidime—Diarrhoea—Fluorouracil—colon cancer	0.00277	0.00277	CcSEcCtD
Ceftazidime—Thrombocytopenia—Capecitabine—colon cancer	0.00277	0.00277	CcSEcCtD
Ceftazidime—Vomiting—Vincristine—colon cancer	0.00276	0.00276	CcSEcCtD
Ceftazidime—Skin disorder—Capecitabine—colon cancer	0.00275	0.00275	CcSEcCtD
Ceftazidime—Rash—Vincristine—colon cancer	0.00274	0.00274	CcSEcCtD
Ceftazidime—Dermatitis—Vincristine—colon cancer	0.00274	0.00274	CcSEcCtD
Ceftazidime—Headache—Vincristine—colon cancer	0.00272	0.00272	CcSEcCtD
Ceftazidime—Angiopathy—Methotrexate—colon cancer	0.00269	0.00269	CcSEcCtD
Ceftazidime—Vomiting—Irinotecan—colon cancer	0.00269	0.00269	CcSEcCtD
Ceftazidime—Immune system disorder—Methotrexate—colon cancer	0.00268	0.00268	CcSEcCtD
Ceftazidime—Dizziness—Fluorouracil—colon cancer	0.00268	0.00268	CcSEcCtD
Ceftazidime—Rash—Irinotecan—colon cancer	0.00267	0.00267	CcSEcCtD
Ceftazidime—Dermatitis—Irinotecan—colon cancer	0.00266	0.00266	CcSEcCtD
Ceftazidime—Headache—Irinotecan—colon cancer	0.00265	0.00265	CcSEcCtD
Ceftazidime—Hypotension—Capecitabine—colon cancer	0.00265	0.00265	CcSEcCtD
Ceftazidime—Nausea—Vincristine—colon cancer	0.00258	0.00258	CcSEcCtD
Ceftazidime—Vomiting—Fluorouracil—colon cancer	0.00258	0.00258	CcSEcCtD
Ceftazidime—Rash—Fluorouracil—colon cancer	0.00255	0.00255	CcSEcCtD
Ceftazidime—Dermatitis—Fluorouracil—colon cancer	0.00255	0.00255	CcSEcCtD
Ceftazidime—Paraesthesia—Capecitabine—colon cancer	0.00254	0.00254	CcSEcCtD
Ceftazidime—Headache—Fluorouracil—colon cancer	0.00254	0.00254	CcSEcCtD
Ceftazidime—Dysgeusia—Methotrexate—colon cancer	0.00253	0.00253	CcSEcCtD
Ceftazidime—Nausea—Irinotecan—colon cancer	0.00251	0.00251	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Capecitabine—colon cancer	0.00244	0.00244	CcSEcCtD
Ceftazidime—Vision blurred—Methotrexate—colon cancer	0.00243	0.00243	CcSEcCtD
Ceftazidime—Pain—Capecitabine—colon cancer	0.00242	0.00242	CcSEcCtD
Ceftazidime—Nausea—Fluorouracil—colon cancer	0.00241	0.00241	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Capecitabine—colon cancer	0.00232	0.00232	CcSEcCtD
Ceftazidime—Leukopenia—Methotrexate—colon cancer	0.00231	0.00231	CcSEcCtD
Ceftazidime—Urticaria—Capecitabine—colon cancer	0.00225	0.00225	CcSEcCtD
Ceftazidime—Abdominal pain—Capecitabine—colon cancer	0.00224	0.00224	CcSEcCtD
Ceftazidime—Body temperature increased—Capecitabine—colon cancer	0.00224	0.00224	CcSEcCtD
Ceftazidime—Convulsion—Methotrexate—colon cancer	0.00224	0.00224	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00218	0.00218	CcSEcCtD
Ceftazidime—Anaphylactic shock—Methotrexate—colon cancer	0.00211	0.00211	CcSEcCtD
Ceftazidime—Hypersensitivity—Capecitabine—colon cancer	0.00209	0.00209	CcSEcCtD
Ceftazidime—Nervous system disorder—Methotrexate—colon cancer	0.00207	0.00207	CcSEcCtD
Ceftazidime—Thrombocytopenia—Methotrexate—colon cancer	0.00206	0.00206	CcSEcCtD
Ceftazidime—Skin disorder—Methotrexate—colon cancer	0.00205	0.00205	CcSEcCtD
Ceftazidime—Pruritus—Capecitabine—colon cancer	0.002	0.002	CcSEcCtD
Ceftazidime—Hypotension—Methotrexate—colon cancer	0.00197	0.00197	CcSEcCtD
Ceftazidime—Diarrhoea—Capecitabine—colon cancer	0.00194	0.00194	CcSEcCtD
Ceftazidime—Paraesthesia—Methotrexate—colon cancer	0.00189	0.00189	CcSEcCtD
Ceftazidime—Dizziness—Capecitabine—colon cancer	0.00187	0.00187	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Methotrexate—colon cancer	0.00182	0.00182	CcSEcCtD
Ceftazidime—Pain—Methotrexate—colon cancer	0.0018	0.0018	CcSEcCtD
Ceftazidime—Vomiting—Capecitabine—colon cancer	0.0018	0.0018	CcSEcCtD
Ceftazidime—Rash—Capecitabine—colon cancer	0.00179	0.00179	CcSEcCtD
Ceftazidime—Dermatitis—Capecitabine—colon cancer	0.00178	0.00178	CcSEcCtD
Ceftazidime—Headache—Capecitabine—colon cancer	0.00177	0.00177	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Methotrexate—colon cancer	0.00172	0.00172	CcSEcCtD
Ceftazidime—Nausea—Capecitabine—colon cancer	0.00168	0.00168	CcSEcCtD
Ceftazidime—Urticaria—Methotrexate—colon cancer	0.00167	0.00167	CcSEcCtD
Ceftazidime—Abdominal pain—Methotrexate—colon cancer	0.00167	0.00167	CcSEcCtD
Ceftazidime—Body temperature increased—Methotrexate—colon cancer	0.00167	0.00167	CcSEcCtD
Ceftazidime—Hypersensitivity—Methotrexate—colon cancer	0.00155	0.00155	CcSEcCtD
Ceftazidime—Pruritus—Methotrexate—colon cancer	0.00149	0.00149	CcSEcCtD
Ceftazidime—Diarrhoea—Methotrexate—colon cancer	0.00144	0.00144	CcSEcCtD
Ceftazidime—Dizziness—Methotrexate—colon cancer	0.00139	0.00139	CcSEcCtD
Ceftazidime—Vomiting—Methotrexate—colon cancer	0.00134	0.00134	CcSEcCtD
Ceftazidime—Rash—Methotrexate—colon cancer	0.00133	0.00133	CcSEcCtD
Ceftazidime—Dermatitis—Methotrexate—colon cancer	0.00133	0.00133	CcSEcCtD
Ceftazidime—Headache—Methotrexate—colon cancer	0.00132	0.00132	CcSEcCtD
Ceftazidime—Nausea—Methotrexate—colon cancer	0.00125	0.00125	CcSEcCtD
